Brontictuzumab

Chemical compound
  • none
IdentifiersCAS Number
  • 1447814-75-6
ChemSpider
  • none
UNII
  • UNY2TQA40E
KEGG
  • D11229
Chemical and physical dataFormulaC6392H9862N1980O1710S50Molar mass143410.36 g·mol−1

Brontictuzumab (INN; development code OMP-52M51) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]

This drug was developed by OncoMed Pharmaceuticals.

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Brontictuzumab, American Medical Association.
  2. ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
  • v
  • t
  • e
Monoclonal antibodies for tumors
Tumor
Human
Mouse
Chimeric
Humanized
Rat/mouse hybrid
Chimeric + humanized
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e